NCT01166984 - AB103 Peptide Antagonist in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Healthy Volunteer Safety Study

Interventions

DRUG

AB103

Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes

DRUG

Placebo

Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes

Trial Locations (1)

University of Maryland School of Medicine, Baltimore